Enjaymo Treatment
Download PDFFDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease. Enjaymo is a humanized monoclonal antibody that is designed to selectively target and inhibit C1s in the classical complement pathway, which is part of the innate immune system.
Copyright © 2022 Cold Agglutinin Disease Foundation - All Rights Reserved.
Contact Us: info@cadfadvocacy.org
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.